Targets › MASP2
1 program from 1 company in 1 trial: 1 Phase 2; Hematology.
Precursor of a serum protease that activates the lectin pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. The lectin complement system is activated following association of lectins, such as MBL2, FCN1, FCN2 or FCN3, to carbohydrates on the pathogen surface. (UniProt, O00187)
Open in Phaseline: the race on MASP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Omeros | narsoplimab Mannan-binding lectin serine protease 2 inhibitor | MASP2 | Phase 2 | Thrombotic Microangiopathies | – |
Thrombotic Microangiopathies (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.